Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired hemophilia A.

Massimo Franchini1

  • 1Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy. mfranchini@mail.univr.it

Hematology (Amsterdam, Netherlands)
|June 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood safety and zoonotic emerging pathogens: now it's the turn of Zika virus!

Blood transfusion = Trasfusione del sangue·2015
Same author

Association between particulate air pollution and venous thromboembolism: A systematic literature review.

European journal of internal medicine·2015
Same author

Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres.

Seminars in thrombosis and hemostasis·2015
Same author

Correlation between ABO Blood Group, and Conventional Hematological and Metabolic Parameters in Blood Donors.

Seminars in thrombosis and hemostasis·2015
Same author

Alcohol consumption and venous thromboembolism: friend or foe?

Internal and emergency medicine·2015
Same author

Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature.

Seminars in thrombosis and hemostasis·2015
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026
See all related articles

Acquired hemophilia A is a rare autoimmune bleeding disorder caused by antibodies against factor VIII. Effective management involves controlling bleeding and suppressing the inhibitor using bypassing agents and immunosuppressive therapies.

Area of Science:

  • Hematology
  • Autoimmune Disorders
  • Immunology

Background:

  • Acquired hemophilia A (AHA) is a rare, severe autoimmune bleeding disorder.
  • It arises from autoantibodies targeting clotting factor VIII.
  • The etiology is often obscure, with half of cases linked to other conditions.

Purpose of the Study:

  • To review the diagnosis and management of acquired hemophilia A.
  • To discuss current and emerging therapeutic strategies for AHA.
  • To highlight the importance of controlling acute bleeding and eliminating inhibitors.

Main Methods:

  • Review of current literature on acquired hemophilia A.
  • Analysis of therapeutic approaches including bypassing agents and immunosuppression.
  • Discussion of novel strategies like anti-CD20 therapy and immune tolerance.

Related Experiment Videos

Main Results:

  • Bypassing agents (activated prothrombin complex concentrates, recombinant activated factor VII) have reduced mortality in patients with high-titer inhibitors.
  • Immunosuppressive therapy (corticosteroids, cytotoxic agents) achieves long-term inhibitor suppression in up to 70% of cases.
  • New strategies show promise for improved prognosis.

Conclusions:

  • Prompt diagnosis and management are crucial for controlling acquired hemophilia A.
  • Bypassing agents and immunosuppression are effective in managing acute bleeding and inhibitors.
  • Emerging therapies offer improved long-term outcomes for AHA patients.